L-Tryptophan: A Pharmaceutical Detective Story

Centers for Disease Control : Eosinophilia-myalgia syndrome and L-tryptophan

containing products—New Mexico, Minnesota, Oregon, and New York, 1989 . MMWR 38:785-788, 1989

Health and Human Services Press Release, November 17,1989

Ama Chemical Laboratory: Elixir of sulfanilamide massengill . JAMA 109:1531-1539,1937

Federal Food, Drug and Cosmetic Act, 21 USC 301-392, 1938

1972 ban on diet pill was ignored by manufacturers, laxly enforced by FDA. The Washington Post, September 5, 1990, p A15

Swygert LA , Maes EF , Sewell LE , et al: Eosinophila-myalgia syndrome—Results of national surveillance . JAMA 264:1698-1703,1990

Process for producing L-tryptophan, and a pure culture of a microorganism strain used in said process. US Patent 4,363,875, December 14, 1982

Process for producing L-tryptophan by fermentation. US Patent 4,560,652, December 24, 1985

What's behind the L-tryptophan ban? Med Sci Bull 12:1-2, 1990

Atlanta Constitution, April 30, 1990, p A1

Belongia EA , Hedberg CW , Gleich GJ , et al: An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 323:357-365,1990

Centers for Disease Control : Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome . MMWR 39:589-591,1990

Centers for Disease Control : Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome . MMWR 39:789-790, 1990

Milne MD : Pharmacology of amino acids. Clin Pharmacol Ther 9:484-515, 1968 15. Hartman E. : L-tryptophan: A rational hypnoticwith clinical potential. Am J Psychiatry 134:366-438,1977

Freese A. , Schwartz KJ , and During M. : Potential neurotoxicity of tryptophan. Ann Intern Med 108:312-313, 1988

Toxic Epidemic Study Group : Toxic epidemic syndrome, Spain, 1981. Lancet 1:697-702,1982

Buchanan Rrc , Gordon DA , Muckle TJ , et al: The eosinophilic fasciitis syndrome after phenytoin (Dilantin) therapy. J Rheumatol 7:733-736, 1980

Ellman L. , Miller L. , and Rappeport J. : Leukopheresis therapy of a hypereosinophilic disorder. JAMA 230:100-1-1005, 1974

Davis P. , Hughes Grv : Significance of eosinophilia during gold therapy. Arthritis Rheum 17:964-968, 1974

Kilbourne EM , Swygert LA , Philen RM , et al: Interim guidance on the eosinophilia-myalgia syndrome. Ann Intern Med 112:85-86, 1990

Clauw DJ , Nashel DJ , Umhau A. , et al: Tryptophan-associated eosinophilic connective-tissue disease. A new clinical entity? JAMA 263:1502-1506, 1990

Smith BE , Dyck PJ : Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Neurology 40:1035-1040, 1990

Martin RW , Duffy J. , Engel AG , et al: The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med 113:124-134, 1990

Lee P. : Eosinophilic fasciitis—New associations and current perspectives . J Rheumatol 8:6-8,1981

Lakhanpal S. , Ginsburg WW , Michet CJ , et al: Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17:221-231, 1988

Chusid MJ , Dale DC , West BC , et al: The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine 54:1-27, 1975

Crofford LJ , Rader JI , Dalakas MC , et al: L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest 86:1757-1763, 1990

Farci AS : The idiopathic hypereosinophilic syndrome. Ann Intern Med 97:78-92, 1982

Clauw DJ , Nashel DJ , Andrew V. , et al: Tryptophan-associated eosinophilic connective-tissue disease: A new clinical entity? JAMA 263:1502-1506, 1990